0000939767-18-000106.txt : 20180524
0000939767-18-000106.hdr.sgml : 20180524
20180524202456
ACCESSION NUMBER: 0000939767-18-000106
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180522
FILED AS OF DATE: 20180524
DATE AS OF CHANGE: 20180524
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WILLSEY LANCE
CENTRAL INDEX KEY: 0001202106
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30235
FILM NUMBER: 18859442
MAIL ADDRESS:
STREET 1: C/O EXELIXIS INC
STREET 2: 170 HARBOR WAY
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94083
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EXELIXIS, INC.
CENTRAL INDEX KEY: 0000939767
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 043257395
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0102
BUSINESS ADDRESS:
STREET 1: 210 E. GRAND AVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 6508377000
MAIL ADDRESS:
STREET 1: 210 E. GRAND AVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS INC
DATE OF NAME CHANGE: 20000207
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20000106
4
1
wf-form4_152720783720964.xml
FORM 4
X0306
4
2018-05-22
0
0000939767
EXELIXIS, INC.
EXEL
0001202106
WILLSEY LANCE
C/O EXELIXIS, INC.
210 E. GRAND AVE.
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
Common Stock
2018-05-22
4
S
0
50000
21.40
D
418273
D
Option (right to buy)
20.5
2018-05-24
4
A
0
31167
0
A
2018-05-24
2025-05-23
Common Stock
31167.0
31167
D
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.26 to $21.60. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4.
Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates.
/s/ Jennifer Drimmer Rokovich, Attorney in Fact
2018-05-24